NCT00680784已完成3 期
Protocol HKT-500-US10: A Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HKT-500 in the Treatment of Pain Associated With Grade I or Grade II Ankle Sprain
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 260
- 试验地点
- 1
- 主要终点
- Pain Assessment
研究概览
简要总结
The objective of this study is to demonstrate the multiple-dose efficacy and safety of HKT-500 for the treatment of ankle sprain.
详细描述
Randomized, double-blind, placebo-controlled, multicenter study in men and women 18 years of age or older who have a painful, acute, benign, ankle sprain of the lateral ligament(s) within the previous 48 hours.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Grade I or Grade II Ankle Sprain.
排除标准
- •The subject is a women of childbearing potential who has a positive urine pregnancy test, who is lactating, who is not surgically sterile (by tubal ligation or hysterectomy), or at least 2 years postmenopausal, and has not practice an acceptable form of birth control (defined as the use of an intrauterine device with spermicide, a barrier method with spermicide, condoms with spermicide, subdermal implant, oral contraceptives, or abstinence) for at least 2 months prior to Visit 1.
研究组 & 干预措施
HKT-500 Ketoprofen Topical Patch
Experimental
Randomized, double-blind, placebo-controlled, multicenter study in men and women 18 years of age or older who have a painful, acute, benign, ankle sprain of the lateral ligament(s) within the previous 48 hours.
干预措施: HKT-500 Ketoprofen Topical Patch (Drug)
Placebo Patch
Placebo Comparator
Treatment with placebo patch
干预措施: Placebo Patch (Other)
结局指标
主要结局
Pain Assessment
时间窗: 2 Weeks
次要结局
- Safety Assessment(2 Weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
HKT-500 in the Treatment of Adult Patients With Ankle SprainAnkle SprainNCT00927641Hisamitsu Pharmaceutical Co., Inc.240
已完成
3 期
HKT-500 in Adult Patients With Shoulder PainPainNCT00680472Hisamitsu Pharmaceutical Co., Inc.368
已完成
2 期
HKT-500-US12 In Adult Patients With OA Knee PainOsteoarthritis, KneeNCT00647231Hisamitsu Pharmaceutical Co., Inc.300
已完成
2 期
A Study of HQK-1001 in Patients With Sickle Cell DiseaseSickle Cell DisordersHemoglobin S DiseaseSickling Disorder Due to Hemoglobin SSickle Cell DiseaseSickle Cell AnemiaNCT01322269HemaQuest Pharmaceuticals Inc.52
招募中
2 期
HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K MutationMelanomaNCT05263453Shanghai Kechow Pharma, Inc.104